Melatonin Mitigates Doxorubicin‐Induced Cardiotoxicity by Targeting the USP18/PKM2 Axis Without Compromising Antitumor Efficacy
4 affiliations
- 1Institute of Cardiovascular Diseases The First Affiliated Hospital of Dalian Medical University Dalian P. R. China
- 2Department of Occupational and Environmental Health School of Public Health Dalian Medical University Dalian P. R. China
- 3Department of Hematology The First Affiliated Hospital of Dalian Medical University Dalian P. R. China
- 4Department of General Surgery The First Affiliated Hospital of Dalian Medical University Dalian P. R. China
Abstract
Doxorubicin (DOX) remains a widely used chemotherapeutic drug, yet its clinical value is constrained by pronounced cardiotoxicity. Although melatonin is known to protect the heart, how it counters DOX‐induced cardiotoxicity (DIC), and whether it interferes with chemotherapy, remains unclear. Here we set out to define how melatonin protects the heart during DOX treatment and to test whether this protection holds in tumor‐bearing animals. We used acute and chronic DIC mouse models together with a syngeneic melanoma‐bearing model, and combined transcriptomic profiling, pharmacological intervention, cardiomyocyte‐specific USP18 overexpression and knockout, co‐immunoprecipitation, mass spectrometry, ubiquitination assays, and PKM2 inhibitor treatment. Melatonin markedly improved cardiac function, an effect exerted mainly via the MT1/2 receptors. Mechanistically, DOX activated STAT1, which in turn drove myocardial USP18 upregulation. USP18 bound PKM2 and stabilized it through removing K33‐linked ubiquitin chains while favoring K27‐linked ubiquitination—thereby aggravating cardiac injury. Overexpressing USP18 specifically in cardiomyocytes worsened DIC and abolished the protection conferred by melatonin, whereas deleting USP18 or inhibiting PKM2 reproduced melatonin's benefits. Notably, in bearing melanoma or lymphoma, melatonin relieved DIC without weakening the antitumor activity of DOX. Together, these findings define a previously unrecognized cardioprotective pathway and provide preclinical support for melatonin as a safe adjunct therapy in cardio‐oncology.
Related
- Extracellular vesicle-encapsulated GDF15 alleviates doxorubicin-induced cardiotoxicity via the SUB1/TERT/TPP signalling axis
- Immune Pathways in Doxorubicin Cardiotoxicity: A Cardio-Immunology Perspective
- Precise immunomodulation by mesenchymal stem cells mitigates hepatitis B virus-specific CD8⁺ T cell-mediated acute liver injury without compromising viral clearance
- Chamber–Specific Molecular Profiling of Doxorubicin-Induced Cardiotoxicity via Integrated Multi-Omics Analysis
- Polyphenols and Flavonoids in microRNA-Regulated Pathways of Doxorubicin-Induced Cardiotoxicity: Mechanistic Evidence, Biomarker Potential and Translational Gaps
BibTeX
@article{feng2026melatonin,
title = {{Melatonin Mitigates Doxorubicin‐Induced Cardiotoxicity by Targeting the USP18/PKM2 Axis Without Compromising Antitumor Efficacy}},
author = {Zhenyu Feng and Yijin Yang and Jie Bai and Pengqi Sun and Xuyang Sun and Jinshu Shang and Yang Liu and Zhen Ning and Ningning Zhang and Yun‐long Xia and Yunpeng Xie},
journal = {Advanced Science},
year = {2026},
month = oct,
doi = {10.1002/advs.78431},
url = {https://doi.org/10.1002/advs.78431},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Melatonin Mitigates Doxorubicin‐Induced Cardiotoxicity by Targeting the USP18/PKM2 Axis Without Compromising Antitumor Efficacy
AU - Zhenyu Feng
AU - Yijin Yang
AU - Jie Bai
AU - Pengqi Sun
AU - Xuyang Sun
AU - Jinshu Shang
AU - Yang Liu
AU - Zhen Ning
AU - Ningning Zhang
AU - Yun‐long Xia
AU - Yunpeng Xie
PY - 2026
DA - 2026/10/26
JO - Advanced Science
DO - 10.1002/advs.78431
UR - https://doi.org/10.1002/advs.78431
AB - Doxorubicin (DOX) remains a widely used chemotherapeutic drug, yet its clinical value is constrained by pronounced cardiotoxicity. Although melatonin is known to protect the heart, how it counters DOX‐induced cardiotoxicity (DIC), and whether it interferes with chemotherapy, remains unclear. Here we set out to define how melatonin protects the heart during DOX treatment and to test whether this protection holds in tumor‐bearing animals. We used acute and chronic DIC mouse models together with a syngeneic melanoma‐bearing model, and combined transcriptomic profiling, pharmacological intervention, cardiomyocyte‐specific USP18 overexpression and knockout, co‐immunoprecipitation, mass spectrometry, ubiquitination assays, and PKM2 inhibitor treatment. Melatonin markedly improved cardiac function, an effect exerted mainly via the MT1/2 receptors. Mechanistically, DOX activated STAT1, which in turn drove myocardial USP18 upregulation. USP18 bound PKM2 and stabilized it through removing K33‐linked ubiquitin chains while favoring K27‐linked ubiquitination—thereby aggravating cardiac injury. Overexpressing USP18 specifically in cardiomyocytes worsened DIC and abolished the protection conferred by melatonin, whereas deleting USP18 or inhibiting PKM2 reproduced melatonin's benefits. Notably, in bearing melanoma or lymphoma, melatonin relieved DIC without weakening the antitumor activity of DOX. Together, these findings define a previously unrecognized cardioprotective pathway and provide preclinical support for melatonin as a safe adjunct therapy in cardio‐oncology.
SN - 2198-3844
ER -